
Data on advanced prostate cancer (PCa) suggest more prior systemic therapies might reduce tumour immune responsiveness. In treatment-naïve primary PCa, recent work correlated intratumoral plasma cell content with enhanced tumour immune responsiveness. We sought to identify features of localized PCa at a high risk of recurrence following local treatment with high plasma cell content to help focus future immune-based neoadjuvant trials. The signature showed castration-resistant tumours (n = 101) with more prior systemic therapies contained lower plasma cell content. Markers of plasma cell activity might be leveraged to augment clinical trial targeting and selection and better understand the potential for immune-based treatments in patients with PCa at a high risk of recurrence following local treatment.
Like
Save
Share